首页> 外文期刊>Bangladesh Critical Care Journal >Microbiological profile and antibiotic susceptibility pattern in Blood stream infections in patients with Acute Cholangitis: A prospective observational study
【24h】

Microbiological profile and antibiotic susceptibility pattern in Blood stream infections in patients with Acute Cholangitis: A prospective observational study

机译:急性胆管炎患者血流感染中的微生物型材和抗生素易感性模式:初步观察研究

获取原文
           

摘要

Background: I analyzed the organisms isolated from the blood of patients with acute cholangitis and determined their antibiotic resistance characteristics. In addition, I evaluated risk factors associated with antibiotic-resistant bacteria and their impact on clinical outcomes. Methods: 113 consecutive cases of acute cholangitis who met the diagnostic criteria were included in the study. Acute cholangitis was defined by TG18 criteria. Blood culture was obtained from every patient. The microbiological results of blood cultures & the antibiotic susceptibility pattern of the organisms were analyzed by SPSSv22.0. Multivariate analysis was performed to identify risk factors associated with antibiotic resistance & mortality. Result: Among 113 patients, 71(62.8%) were male & the median age was 51 years. Choledocholithiasis was the most common underlying biliary disease followed by malignant and benign strictures. Severe cholangitis occurred in 17(15%) cases. 32(28.3%) cases had nosocomial infection. Causative organisms were isolated from 55(48.7%) of 113 blood cultures. Escherichia coli was the most common bacterium isolated (36.36%) from blood, followed by Klebsiella pneumoniae (23.64%), Pseudomonas aeruginosa (7.27%) & Enterococcus (7.27%). Anaerobic bacteria were isolated from 5(9.09%) specimens. Multiple organisms were isolated in 6(10.91%) specimens. Most organisms were susceptible to meropenem (86.7%), imipenem (83.1%), colistin (89.1%), amikacin (76.1%), piperacillin-tazobactam (79.6%) & polymyxin-B (83.3%). Multidrug resistant bacteria comprised 30.91% of blood isolates. Risk factors associated with antibiotic resistance were presence of an indwelling biliary device (OR:7.7), prior biliary intervention (OR:6.167) and a nosocomial source of infection (OR:9.09). Thirteen (11.5%) patients died from acute cholangitis. Risk factors associated with mortality were severe cholangitis (OR:6.9), malignant biliary obstruction (OR:8.4), nosocomial infection (OR:7.5) and isolation of multidrug resistant organisms in blood (OR:6.9). Conclusion: E. coli was the most common organism isolated, followed by Klebsiella, Pseudomonas & Enterococcus. Colistin, meropenem, polymyxin-B, imipenem, amikacin & piperacillin-tazobactam were the most effective of all antibiotics. Risk factors associated with isolation of multidrug resistant bacteria from blood were presence of an indwelling biliary device, prior biliary intervention and a nosocomial source of infection. Risk factors associated with mortality were severe cholangitis, malignant biliary obstruction, nosocomial infection and isolation of multidrug resistant organisms in blood.
机译:背景:我分析了急性胆管炎患者血液中分离的生物体,并确定了它们的抗生素抗性特征。此外,我评估了与抗生素抗性细菌相关的危险因素及其对临床结果的影响。方法:在研究中纳入了符合诊断标准的113例急性胆管炎。急性胆管炎由TG18标准定义。血液培养是从每位患者获得的。通过SPSSV222.0分析了血液培养和生物体的抗生素敏感性模式的微生物结果。进行多变量分析以确定与抗生素抗性和死亡率相关的危险因素。结果:在113名患者中,71名(62.8%)是男性和中位年龄为51岁。 Choledocholithiaisis是最常见的潜水疾病,然后是恶性和良性狭窄。严重的胆管炎发生在17例(15%)的病例中发生。 32(28.3%)病例具有医院感染。分离出致病生物,从55例(48.7%)的113个血培养物中分离。大肠杆菌是来自血液中最常见的细菌(36.36%),其次是Klebsiella Pneumoniae(23.64%),假单胞菌铜绿假单胞菌(7.27%)和肠球菌(7.27%)。厌氧细菌分离5(9.09%)标本。在6(10.91%)标本中分离多种生物。大多数生物易于梅洛涅姆(86.7%),亚氨植物(83.1%),乳蛋白(89.1%),氨基辛蛋白(76.1%),哌啶素-Tazobactam(79.6%)和多粘菌素-B(83.3%)。多药抗性细菌包含30.91%的血液分离物。与抗生素抗性相关的危险因素是存在留置胆道装置(或:7.7),先前胆道干预(或:6.167)和医院感染源(或:9.09)。十三(11.5%)患者死于急性胆管炎。与死亡率相关的危险因素是严重的胆管炎(或:6.9),恶性胆管阻塞(或:8.4),医院感染(或:7.5),并在血液中分离多药物(或:6.9)。结论:大肠杆菌是被隔离的最常见的生物,其次是Klebsiella,假单胞菌和肠球菌。 Colistin,Meropenem,Polymyxin-B,Imipenem,Amikacin和Piperacillin-Tazobactam是所有抗生素最有效的。与血液中多药抗性细菌分离相关的危险因素是存在的介绍胆道装置,先前胆道干预和医院感染源。与死亡率相关的危险因素是严重的胆管炎,恶性胆道阻塞,医院感染,血液中多药物的分离。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号